Holtick U - Search Results

1

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.

Eberhardt KA, Jung V, Knops E, Heger E, Wirtz M, Steger G, Kaiser R, Affeldt P, Holtick U, Klein F, Scheid C, Di Cristanziano V. Eberhardt KA, et al. Among authors: holtick u. Bone Marrow Transplant. 2023 Jun;58(6):639-646. doi: 10.1038/s41409-023-01944-2. Epub 2023 Mar 3. Bone Marrow Transplant. 2023. PMID: 36869190 Free PMC article.

2

Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation.

Holtick U, von Bergwelt-Baildon M. Holtick U, et al. Expert Rev Vaccines. 2009 May;8(5):519-23. doi: 10.1586/erv.09.24. Expert Rev Vaccines. 2009. PMID: 19397408 No abstract available.

3

Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells.

Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP. Haniffa MA, et al. Among authors: holtick u. J Immunol. 2007 Aug 1;179(3):1595-604. doi: 10.4049/jimmunol.179.3.1595. J Immunol. 2007. PMID: 17641026

4

U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.

Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S; Photopheresis Expert Group. Scarisbrick JJ, et al. Among authors: holtick u. Br J Dermatol. 2008 Apr;158(4):659-78. doi: 10.1111/j.1365-2133.2007.08415.x. Epub 2008 Jan 30. Br J Dermatol. 2008. PMID: 18241274

5

Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells.

Holtick U, Marshall SR, Wang XN, Hilkens CM, Dickinson AM. Holtick U, et al. Transplantation. 2008 Mar 15;85(5):757-66. doi: 10.1097/TP.0b013e31816650f6. Transplantation. 2008. PMID: 18337671

6

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia.

Holtick U, Marshall SR, O'Brien SG, Collin MP. Holtick U, et al. Blood. 2007 Dec 15;110(13):4622-3. doi: 10.1182/blood-2007-09-111757. Blood. 2007. PMID: 18056852 Free article. No abstract available.

7

Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?

Holtick U, Klein-Gonzalez N, von Bergwelt-Baildon MS. Holtick U, et al. Immunotherapy. 2011 Mar;3(3):301-4. doi: 10.2217/imt.10.118. Immunotherapy. 2011. PMID: 21395370 Free article. No abstract available.

8

STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis.

Holtick U, Vockerodt M, Pinkert D, Schoof N, Stürzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Löffler D, Horn F, Trümper L, Kube D. Holtick U, et al. Leukemia. 2005 Jun;19(6):936-44. doi: 10.1038/sj.leu.2403750. Leukemia. 2005. PMID: 15912144

9

STAT3 is constitutively activated in Hodgkin cell lines.

Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H. Kube D, et al. Among authors: holtick u. Blood. 2001 Aug 1;98(3):762-70. doi: 10.1182/blood.v98.3.762. Blood. 2001. PMID: 11468177 Free article.

10

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C. Chemnitz JM, et al. Among authors: holtick u. Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17. Ann Hematol. 2012. PMID: 21584670

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page